OXFORD, England, July 12, 2011 /PRNewswire/ —
PharmaVentures Limited, experts in deals and alliances, are
pleased to announce that they have been engaged by Avexa Limited to
seek an out-licensing partner for apricitabine (ATC), a late-stage,
novel treatment for HIV infection. The engagement will
utilise PharmaVentures’ global transactional expertise in the
healthcare and investment business sectors.
Dr Fintan Walton, CEO, PharmaVentures, commented, “We are
delighted to have been chosen by Avexa to assist in achieving its
business goal of maximising the return on investment in its
development compound apricitabine (ATC). With 20 years’
experience of deals and alliances, PharmaVentures can provide Avexa
with immediate access to extensive licensing expertise and a
network of key decision makers in relevant companies.”
Iain Kirkwood, Chairman of Avexa, said, “The appointment of
PharmaVentures to work with and complement our management team is
the next logical step in the commercialisation of ATC following our
successful regulatory meeting with the FDA earlier this year.
PharmaVentures have an excellent reputation and track record in
this area.”
ATC is a novel nucleoside, a class of compound known to be a
vital component of anti-HIV therapy. ATC offers a new
extension to existing therapies in the treatment of drug-resistant
HIV, especially for those patients with limited remaining
therapeutic options.
PharmaVentures is a leading life sciences transaction advisory
firm with strong capabilities in finding and evaluating
opportunities and negotiating deals. The licensing team has
an established track record in generating outstanding value for
PharmaVentures’ clients and has assisted in over 100 transactions
in the past 20 years.
About PharmaVentures Limited
PharmaVentures Limited (http://www.pharmaventures.com)
is a leading inte
‘/>”/>
SOURCE
